Last reviewed · How we verify
Claforan (CEFOTAXIME)
Claforan (Cefotaxime) is a cephalosporin antibacterial drug developed by Sanofi Aventis US and currently owned by Sterimax. It is a small molecule that has been FDA-approved since 1981 for various bacterial infections, including bacterial arthritis, meningitis, and septicemia. Claforan is off-patent and has multiple generic manufacturers. Key safety considerations include its short half-life of 1.2 hours. Claforan is a broad-spectrum antibiotic that treats a range of bacterial infections.
At a glance
| Generic name | CEFOTAXIME |
|---|---|
| Sponsor | Sterimax |
| Drug class | Cephalosporin Antibacterial |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 1981 |
Approved indications
- Bacterial arthritis
- Bacterial infection due to Klebsiella pneumoniae
- Bacterial infection due to Serratia
- Bacterial meningitis
- Bacterial pneumonia
- Bacterial septicemia
- Bacterial urinary infection
- Bacteroides Endometritis
- Bacteroides Pelvic Cellulitis
- Bacteroides Pelvic Inflammatory Disease
- Cesarean Section Infection Prevention
- Citrobacter Urinary Tract Infection
- Clostridium Endometritis
- Clostridium Pelvic Cellulitis
- Clostridium Pelvic Inflammatory Disease
- Clostridium Peritonitis
- E. Coli Endometritis
- E. Coli Pelvic Cellulitis
- E. Coli Pelvic Inflammatory Disease
- E. Coli Peritonitis
Common side effects
Key clinical trials
- Study of Ceftriaxone and Benzathine Penicillin G During Pregnancy
- A Randomised Study to Compare the Efficacy and Safety of Extended and Intermittent Infusion of Beta-lactams in Critically Ill Paediatric Patients. (PHASE4)
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
- Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing (PHASE2)
- Ceftriaxone Pulse Dose for Post-Treatment Lyme Disease (EARLY_PHASE1)
- Aminoglycosides in Early Sepsis (PHASE4)
- Precision Antibiotic Dosing for Appendectomy (PHASE1)
- Short Versus Standard of Care Antibiotic Duration for Children Hospitalized for CAP (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Claforan CI brief — competitive landscape report
- Claforan updates RSS · CI watch RSS
- Sterimax portfolio CI